research Ritlecitinib: First Approval
Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.
Search
for
Sort by
Research
150-180 / 1000+ results research Vemurafenib-induced pityriasis amiantacea: a case report
Vemurafenib can cause scalp issues but can be managed without changing the dose.
research Biotransformation of tirilazad in human: 4. effect of finasteride on tirilazad clearance and reduced metabolite formation.
research THERAPEUTIC CHALLENGES IN POLYAUTOIMMUNITY: ANIFROLUMAB FOR LUPUS ERYTHEMATODES IN OVERLAPPING AUTOIMMUNE SYNDROMES
Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
research RASopathic Skin Eruptions during Vemurafenib Therapy
Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.
research Flexabrasion Applied to the Evaluation of the Photodegradation of Hair Fibers
research “Efficacy of Platelet-Rich Plasma Plus Basic Fibroblast Growth Factor on the Treatment of Androgenic Alopecia”
PRPF is a safer and more effective treatment for hair loss than PRP.
research Anticoagulant-free preparation of autologous platelet-rich plasma (PRP) / fluid platelet-rich fibrin (f-PRF): a pre-clinical comparative performance study
Exprecell™ is as effective as traditional methods but produces more f-PRF and is simpler to use.
research Further research needed if finasteride is to become standard of care for frontal fibrosing alopecia (FFA)
More research needed to confirm finasteride as standard treatment for FFA.
research Correction to: An evaluation of the federal adverse events reporting system data on adverse effects of 5‑alpha reductase inhibitors
The correction states that the label change for Finasteride was in 2012, leading to more reports of side effects from non-healthcare people.
research P133 Anifrolumab treatment improves quality of life and decreases corticosteroid use in patients with SLE
Anifrolumab improves quality of life and reduces steroid use in SLE patients.
research COMBINATION OF AN ANTIANDROGEN AND A 5α-REDUCTASE INHIBITOR: A FURTHER STEP TOWARDS TOTAL ANDROGEN BLOCKADE?
Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
research Is SFRP-4 an early potential biomarker related to diabetes and hypertension, in patients with androgenic alopecia?
SFRP-4 might be an early indicator of diabetes and hypertension in men with androgenic alopecia.